Biocon sees GLP-1 weight-loss therapy as a future growth driver

Biocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 India launch. CEO Shreehas Tambe said both portfolios are complementary. Biocon aims to leverage its insulin experience for GLP-1 success, following US FDA approval for insulin aspart and India approval for liraglutide. External risks remain a key concern.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw4pEIK
via IFTTT